There’s still a long way to go, but the newcomer is off to a good start.
News & Analysis: Bluebird Bio
Wall Street has soured on the company's prospects as it eyes a transition to commercial operations.
Zynteglo was recently approved in Europe.
Will this bluebird ever bring happiness to its shareholders?
The short answer: in great shape.
Following European approval earlier this month, bluebird bio announced its beta-thalassemia gene therapy will launch with a sky-high price tag.
These stocks are leading the way in their respective areas in battling cancer.
European regulators have signed off on the biotech's revolutionary gene therapy for beta-thalassemia.
These drugs and the biotechs that make them could be on the way to tremendous success in the near future.
An approval for Zynteglo is imminent.